Login Register
icon_bulk_orderBulk order Acrobiosystems for English
There is no goods in the shopping cart !
A B C D E F G H I J K L M N O P Q R S T U V W X Y Z 0-9
Your Position: Home > CD30


Brief Information

Name:Tumor necrosis factor receptor superfamily member 8
Target Synonym:CD30,CD30L receptor,TNFRSF8,Lymphocyte activation antigen CD30,TNF Receptor Superfamily Member 8,D1S166E,Tumor Necrosis Factor Receptor Superfamily, Member 8,Cytokine Receptor CD30,CD30 Antigen,Ki-1,Ki-1 Antigen,Tumor Necrosis Factor Receptor Superfamily Member 8
Number of Launched Drugs:1
Number of Drugs in Clinical Trials:14
Lastest Research Phase:Approved

Product ListCompare or Buy

ACRO Quality

Part of Bioactivity data

CD0-HF2H4-Cell-based assay
FACS assay shows that recombinant Biotinylated FACS

2e5 of anti-CD30 CAR-293 cells were stained with 100 μL of 1 μg/mL of FITC-Labeled Human CD30, His Tag (Cat. No.CD0-HF2H4) and negative control protein respectively, FITC signal was used to evaluate the binding activity (QC tested).

CD0-HP2E3-Cell-based assay

5e5 of anti-CD30 CAR-293 cells were stained with 100 μL of 1:50 dilution (2 μL stock solution in 100 μL FACS buffer) of PE-Labeled Human CD30, His Tag (Cat. No. CD0-HP2E3) and negative control protein respectively. PE signal was used to evaluate the binding activity (QC tested).


Loaded Human CD30 Ligand, His Tag (Cat. No. CDL-H524b) on HIS1K Biosensor, can bind Human CD30 Protein, Llama IgG2b Fc Tag (Cat. No. TN8-H5250) with an affinity constant of 55.5 nM as determined in BLI assay (ForteBio Octet Red96e) (Routinely tested).


Loaded Biotinylated Human CD30, Avitag,His Tag (Cat. No. CD0-H82E6) on SA Biosensor, can bind Human CD30 Ligand, His Tag, low endotoxin (Cat. No. CDL-H524b) with an affinity constant of 139 nM as determined in BLI assay (ForteBio Octet Red96e) (Routinely tested).

Customer Reviews

Synonym Name



Human CD30 is also known as TNFRSF8, is a cell membrane protein of the tumor necrosis factor receptor family and tumor marker. TNFRSF-8 is expressed by activated, but not by resting, T and B cells. Also, CD30 is expressed on classical Hodgkin Lymphoma cells together with CD15. CD30 is the receptor for TNFSF8/CD30L. CD30 can interact with TRAF2 and TRAF5, and mediate the signal transduction that leads to the activation of NF-kappa-B. TNFRSF8 may play a role in the regulation of cellular growth and transformation of activated lymphoblasts. TNFRSF8 is a positive regulator of apoptosis, and also has been shown to limit the proliferative potential of autoreactive CD8 effector T cells and protect the body against autoimmunity.

Clinical and Translational Updates

Public Drug Information

Name Research Code Research Phase Company First Brand Name First Approved Country First Indication First Approved Company First Approved Date Indications Clinical Trials
Brentuximab vedotin SGN-30; SGN-35; cAC-10; SGD-1010; cAC10-vcMMAE; cAC10-Val-Cit-MMAE Approved Millennium Pharmaceuticals Inc, Seattle Genetics Inc 安适利, Adcetris Mainland China Lymphoma, Primary Cutaneous Anaplastic Large Cell; Mycosis Fungoides Takeda Pharma A/S 2011-08-19 Mesothelioma; Neoplasms, Germ Cell and Embryonal; Sarcoma, Kaposi; Lymphomatoid Papulosis; Mycosis Fungoides; Lymphoma; Leukemia, Myeloid, Acute; Lymphoma, T-Cell, Cutaneous; Scleroderma, Diffuse; Lymphoma, T-Cell; Lymphoma, Large-Cell, Anaplastic; Lymphoma, Non-Hodgkin; Sezary Syndrome; Lupus Erythematosus, Systemic; Precursor Cell Lymphoblastic Leukemia-Lymphoma; Lymphoma, Primary Cutaneous Anaplastic Large Cell; Lymphoma, T-Cell, Peripheral; Leukemia, Mast-Cell; Enteropathy-Associated T-Cell Lymphoma; Lymphoma, Large B-Cell, Diffuse; Myelodysplastic Syndromes; Mastocytosis, Systemic; Scleroderma, Systemic; Graft vs Host Disease; Neoplasms; Hodgkin Disease; Carcinoma; Anemia, Refractory, with Excess of Blasts; Lymphoma, B-Cell; HIV Infections; Hematologic Diseases; Solid tumours Details

Clinical Drug Information

Name Research Code Research Phase Company Indications Clinical Trials
Anti-CD30 CAR-T cell therapy (National Cancer Institute) Hu30-CD28z Phase 1 Clinical National Cancer Institute Lymphoma Details
Anti CD30 CAR T Cell Therapy (First Song Therapeutics) Zhejiang University Details
MDX-1401 MDX-1401 Medarex Details
Recombinant chimeric anti-CD30 monoclonal antibody-MCC-DM1 F0002-ADC; B-006 Phase 1 Clinical Shanghai Crosslink Pharmaceutical R & D Co Ltd, Shanghai Fudan-Zhangjiang Bio-Pharmaceutical Co Ltd Lymphoma, T-Cell, Peripheral; Hematologic Neoplasms Details
Itezocabtagene autoleucel TT-11 Phase 2 Clinical Tessa Therapeutics Ltd Lymphoma, T-Cell, Peripheral; Lymphoma, B-Cell; Hodgkin Disease; Lymphoma, Large B-Cell, Diffuse; Lymphoma, Extranodal NK-T-Cell; Lymphoma, Large-Cell, Anaplastic Details
CD30.CAR H-27721; CD30.CAR Phase 1 Clinical Baylor College Of Medicine Hodgkin Disease; Lymphoma, Non-Hodgkin Details
Anti-CD30 chimeric antigen receptor T cell therapy (Immune cell) Phase 1 Clinical Immune Cell Inc Hodgkin Disease; Lymphoma, Large-Cell, Anaplastic Details
SGN-CD30C SGN-CD30C Phase 1 Clinical Seattle Genetics Inc Lymphoma Details
Anti-CD30 CAR T-cell therapy (Wuhan Bio-Raid) Phase 1 Clinical Wuhan Bio-Raid Biotechnology Lymphoma, T-Cell, Peripheral; Hematologic Neoplasms; Hodgkin Disease; Lymphoma, Extranodal NK-T-Cell; Lymphoma, T-Cell; Lymphoma, Large-Cell, Anaplastic Details
Chimeric antigen receptor T cell therapeutics (targeted CD19/CD20/CD22/CD30,Shanghai Unicar-Therapy Bio-medicine) Phase 2 Clinical Shanghai Unicar-Therapy Bio-Medicine Technology Co Ltd Pancreatic Neoplasms; Lymphoma, Non-Hodgkin Details
EBV-specific-CAR.CD30 EBV-specific-CAR.CD30; CAR.CD30 EBV-specific-CTLs Phase 1 Clinical Baylor College Of Medicine, Texas Children'S Hospital, Methodist Hospital System Hodgkin Disease; Lymphoma, Non-Hodgkin Details
CD30.CAR-EBVST cell therapy (Baylor College of Medicine) TT-11X Phase 1 Clinical Baylor College Of Medicine, Tessa Therapeutics Ltd Lymphoma, Large B-Cell, Diffuse; Hodgkin Disease; Lymphoma, Extranodal NK-T-Cell Details
AFM-13 AFM-13 Phase 2 Clinical The University Of Texas MD Anderson Cancer Center Lymphoma, T-Cell, Peripheral; Hodgkin Disease; Mycosis Fungoides Details
HSP-CAR-30 HSP-CAR-30 Phase 2 Clinical Fundació Institut De Recerca De L Hodgkin Disease; Lymphoma, T-Cell Details
Anti-CD30 CAR T-cell therapy (General Hospital of the People's Liberation Army/Cellular Biomedicine) CAR30-NKT; CBM-C30.1; CD30ScFv-CD8-CD137-CD3zeta Phase 2 Clinical Pla General Hospital Hodgkin Disease Details
PRA-052 PRA-052 Phase 1 Clinical Prometheus Biosciences Inc Colitis, Ulcerative Details
CD30 biAb-AATC(The Medical College Of Wisconsin Nonprofit) Phase 2 Clinical The Medical College Of Wisconsin Nonprofit Lymphoma, B-Cell; Solid tumours; Chondrosarcoma; Leukemia; Neoplasms; Hodgkin Disease; Neuroblastoma; Lymphoma Details
ATLCAR.CD30 cells (UNC Lineberger Comprehensive Cancer Center) Phase 2 Clinical Unc Lineberger Comprehensive Cancer Center Lymphoma, T-Cell, Peripheral; Lymphatic Diseases; Immunoproliferative Disorders; Hodgkin Disease; Neoplasms; Immune System Diseases; Lymphoproliferative Disorders; Lymphoma, Non-Hodgkin; Lymphoma; Neoplasms, Germ Cell and Embryonal Details

This web search service is supported by Google Inc.

Call us
Call us
North America: +1 800-810-0816 (Toll Free)
Asia & Pacific: +86 400-682-2521
+1 888-377-6111
1 Innovation Way, Newark, DE 19711, USA

Leave a message